Insights From Pharma 2025: Navigating The Evolution Of EU Health Technology Assessment (HTA) Regulation

The EU Health Technology Assessment (HTA) Regulation is now a reality, ushering in a new chapter for pharmaceutical market access across Europe. While the promise of streamlined assessments and faster patient access is significant, the path to effective implementation is not without its complexities.

At Pharma 2025, these challenges and opportunities took center stage in a thought-provoking discussion between Alexander Natz, representing the innovative spirit of EUCOPE, and Herbert Altmann of Cencora, bringing his extensive market access expertise to the table. Their exchange explored critical aspects, including ensuring smaller companies have a voice in the process, addressing resource constraints within HTA bodies, and fostering a collaborative learning environment. Understanding these nuances is crucial for all stakeholders in the pharmaceutical ecosystem.

Delve into the details of their conversation and the future of EU HTA by reading the complete article.